Minocycline and neurodegenerative diseases

Behavioural Brain Research

Volumn 196, Issue 2, 2009, Pages 168-179

  Kim, Hye Sun ^a,b   Suh, Yoo Hun ^a  

^a Seoul National University   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

Alzheimer's disease; Amyotropic lateral sclerosis; Huntington's disease; Ischemia; Minocycline; Neurodegenerative diseases; Parkinson's disease; Spinal cord injury

Indexed keywords

CASPASE 3; CYTOCHROME C; INTERLEUKIN 1BETA CONVERTING ENZYME; METALLOPROTEINASE; MINOCYCLINE; TETRACYCLINE DERIVATIVE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; CELL ACTIVATION; CLINICAL TRIAL; DEGENERATIVE DISEASE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME RELEASE; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HUMAN; HUNTINGTON CHOREA; MICROGLIA; MITOCHONDRIAL PERMEABILITY; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SPINAL CORD INJURY; STROKE; TRAUMATIC BRAIN INJURY;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; HUMANS; MINOCYCLINE; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; SIGNAL TRANSDUCTION;

EID: 57549088119     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2008.09.040     Document Type: Review

References (99)

1. Aronson A.L. Pharmacotherapeutics of the newer tetracyclines. J Am Vet Med Assoc 176 (1980) 1061-1068
2. Luccarini H., Ballerini C., Biagioli T., Biamonte F., Bellucci A., Rosi M.C., et al. Combined treatment with atorvastatin and minocycline suppresses severity of EAE. Exp Neurol 211 1 (2008) 214-226
3. Yong V.W., Wells J., Giuliani F., Casha S., Power C., and Metz L.M. The promise of minocycline in neurology. Lancet Neurol 3 12 (2004) 744-751
4. Sapadin A., and Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 54 2 (2006) 258-265
5. Suk K. Minocycline suppresses hypoxic activation of rodent microglia in culture. Neurosci Lett 366 2 (2004) 167-171
6. Klein N.C., and Cunha B.A. Tetracyclines. Med Clin North Am 79 4 (1995) 789-801
7. Good M.L., and Hussey D.L. Minocycline stain devil?. Br J Dermatol 149 2 (2003) 237-239
8. Stirling D.P., Koochesfahani K.M., Steeves J.D., and Tetzlaff W. Minocycline as a neuroprotective agent. Neuroscientist 11 4 (2005) 308-322
9. Yrjanheikki J., Tikka T., Keinanen R., Goldsteins G., Chan P.H., and Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 96 (1999) 13496-13500
10. Sanchez, Mejia R.O., Ona V.O., Li M., and Friendlander R.M. Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery 48 6 (2001) 1393-1399
11. Zhu S., Stavrovskaya I.G., Drozda M., Kim B.Y., Ona V., Li M., et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417 6884 (2002) 74-78
12. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22 5 (2002) 1763-1771
13. Heo K., Cho Y.J., Cho K.J., Kim H.W., Kim H.J., Shin H.Y., Lee B.I., and Kim G.W. Minocycline inhibits caspase-dependent and -independent cell death pathways and is neuroprotective against hippocampal damage after treatment with kainic acid in mice. Neurosci Lett 398 3 (2006 8) 195-200
14. Chen M., Ona V.O., Li M., Ferrante R.J., Fink K.B., Zhu S., et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6 7 (2000) 797-801
15. Wang X., Zhu S., Drozda M., Zhang W., Stavrovskaya I.G., Cattane o.E., et al. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci USA 100 18 (2003) 10483-10487
16. Popovic N., Schubart A., Goetz B.D., Zhang S.C., Linington C., and Duncan I.D. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol 51 2 (2002) 215-223
17. Choi Y.R., Kim H.S., Shin K.Y., Kim E.M., Kim H.S., Park C.H., et al. Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. Neuropsychopharmacology 32 11 (2007) 2393-2404
18. Pae C.U., Marks D.M., Han C., and Patkar A.A. Does minocycline have antidepressant effect?. Biomed Pharmacotherapy 62 (2008) 308-311
19. Gordon P.H., Moore D.H., Gelinas D.F., Qualls C., Meister M.E., Werner J., et al. Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology 62 (2004) 1845-1847
20. Golub L.M., Soummalarien K., and Sorsa T. Host modulation with tetracyclines and their chemically modified analogues. Curr Opin Dent 2 (1992) 80-90
21. Nelson M.L. Chemical and biological dynamics of tetracyclines. Adv Den Res 12 (1998) 5-11
22. Martin R.B. Tetracyclines and daunorubicin in metal ions in biological system. In: Sigel H. (Ed). Antibiotics and their complexes (1985), Marcel Dekker, New York 19-40
23. Dommergues M.A., Plaisant F., Vemey C., and Gressens P. Early microglial activation following neonatal excitotoxic brain damage in mice: a potential target for neuroprotection. Neuroscience 121 3 (2003) 619-628
24. He Y., Appel S., and Le W. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res 909 (2001) 187-193
25. Brundula V., Rewcastle B., metz L.M., Bernard C.C., and Yong V.W. Targeting leukocyte MMPs and transmigration minocycline as a potential therapy for multiple sclerosis. Brain 125 (2002) 1297-1308
26. Yong V.W., Power C., Forsyth P., and Edwards D.R. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2 (2001) 502-511
27. Filipovic R., and Zecevic N. Neuroprotective role of minocycline in co-cultures of human fetal neurons and microglia. Exp Neurol 211 1 (2008) 41-51
28. Elkelenboom P., Veerhulus R., Familian A., Hoozemans J.J., van Gool W.A., and Rozemuller A.J. Neuroinflammation in plaque and vascular beta-amyloid disorders: clinical and therapeutic implications. Neurodegener Dis 5 3-4 (2008) 190-193
29. Bacskai B.J., Kazdasz S.T., Christie R.H., Carter C., Games D., Seubert P., et al. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 7 3 (2001) 369-372
30. Garcia-Alloza M., Dodwell S.A., Ferrara B.J., Hickey G.A., Hyman B.T., and Bacskal B.J. A limited role for microglia in antibody mediated plaque clearance in APP mice. Neurobiol Dis 28 3 (2007) 286-292
31. Tikka T.M., and Koistinaho J.E. Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol 166 12 (2001) 7527-7533
32. Cagnin A., Brooks D.J., Kennedy A.M., Gunn R.N., Meyers R., Turkheimer F.E., et al. In vivo measurement of activated microglia in dementia. Lancet 358 (2001) 461-467
33. Coraci I.S., Husemann J., Berman J.W., Hulette C., Dufour J.H., Campanella G.K., et al. CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. Am J Pathol 160 January (1) (2002) 101-112
34. Robert M.F. Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 348 (2003) 1365-1375
35. Ekshyyan O., and Aw T.Y. Apoptosis in acute and chronic neurological disorders. Front Biosci 9 (2004) 1567-1576
36. Stirling D.P., Khodarahmi K., Liu J., McPhail L.T., McBride C.B., and Steeves J.D. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci 24 9 (2004) 2182-2190
37. Wang J., Wei Q., Wang C.Y., Hill W.D., Hess D.C., and Dong Z. Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. J Biol Chem 279 19 (2004) 19948-219854
38. Teng Y.D., Choi H., Onario R.C., Zhu S., Desilets F.C., Lan S., et al. Minocycline inhibits contrusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc Natl Acad Sci USA 101 (2004) 3071-3076
39. Mansson R., Hansson M.J., Morota S., Uchino H., Ekdahl C.V.T., and Elmer E. Re-evaluation of mitochondrial permeability transition as a primary neuroprotective target of minocycline. Neurobiol Dis 25 (2007) 198-205
40. Tikka T., Fiebich B.L., Goldsteins G., Keinanen R., and Koistinaho J. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 21 8 (2001) 2580-2588
41. Lin S., Zhang Y., Dodel R., Farlow M.R., Paul S.M., and Du Y. Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons. Neurosci Lett 315 1-2 (2001) 61-64
42. Guo G., and Bhat N.R. p38alpha MAP kinase mediates hypoxia-induced motor neuron cell death: a potential target of minocycline's neuroprotective action. Neurochem Res. 32 12 (2007) 2160-2166
43. Haines J.D., Fragoso G., Hossain S., Mushynski W.E., and Almazan G. p38 Mitogen-activated protein kinase regulates myelination. J Mol Neurosci 35 (2008) 23-33
44. Wada T., and Penninger J.M. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23 16 (2004) 2838-2849
45. Piao C.S., Kim J.B., Han P.L., and Lee J.K. Administration of the p38 MAPK inhibitor SB203580 affords brain protection with a wide therapeutic window against focal ischemic insult. J Neurosci Res 73 4 (2003) 537-544
46. Yrjanheikki J., Keinanen R., Pellikka M., Hokfelt T., and Koisinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 95 (1998) 15769-15774
47. Tang X.N., Wang O., Koike M.A., Chang D., Goris M.L., Blankenbag F.G., et al. Monitoring the protective effects of minocycline treatment with radiolabeled annexin V in an experimental model of focal cerebral ischemia. J Nucl Med 48 11 (2007) 1822-1828
48. Iyirhiaro G.O., Brust T.B., Rashidian J., Galendar Z., Osman A., Phillips M., et al. Delayed combinatorial treatment with flavopiridol and minocycline provides longer term protection for neuronal soma but not dendrites following global ischemia. J Neurochem 105 (2008) 703-713
49. Sanchez E.C. Hyperbaric oxygenation in peripheral nerve repair and regeneration. Neurol Res 29 (2007) 184-198
50. Keilhoff G., Schild L., and Fansa H. Minocycline protects Schwann cells from ischemia-like injury and promotes axonal outgrowth in bioartificial nerve grafts lacking Wallerian degeneration. Exp Neruol 212 (2008) 189-200
51. Tusuji M., Wilson M.A., Lange M.S., and Johnston M.V. Minocycline worsens hypoxic-ischemic brain injury in a neonatal mouse model. Exp Neurol 189 (2004) 2580-2588
52. Guerin C., Laterna J., Masnyk T., Golub L.M., and Brem H. Selective endothelial growth inhibition by tetracyclines that inhibit collagenase. Biochem Biophys Res Commun 188 (1992) 740-745
53. Tamargo R.J., Bok R.A., and Brem H. Angiogenesis inhibition by minocycline. Cancer Res 51 (1991) 672-675
54. Lampl Y., Boaz M., Gilad R., Lorberboym M., Dabby R., Rapoport A., et al. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 69 14 (2007) 1404-1410
55. Marier K., Merkler D., Geber J., Taheri N., Kuhnert A., Williams S.K., et al. Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation. Neurobiol Dis 25 (2007) 514-525
56. Komek B., Storch M.K., Weissert R., Wallstroem E., Stefferl A., Olsson T., et al. Multiple sclerosis and chronic autoimmune encephalitis: a comparative quantative study of axonal injury in active, inactive, and remyelinated lesions. Am H Pathol 157 (2000) 267-276
57. Trapp B.D., Peterson J., Ransohof R.M., Rudick R., Mork S., and Bo L. Axonal transaction in the lesions of multiple sclerosis. N Engl J Med 338 (1998) 278-285
58. Kloppenburg M., Verweij C.L., Miltenburg A.M., Verhoeven A.J., Daha M.R., Dijkmans B.A., et al. The influence of tetracyclines on T cell activation. Clin Exp Immunol 102 3 (1995) 635-641
59. Ruggieri M., Pica C., Lia A., Zimatore G.B., Modesto M., Di Liddo E., et al. Combination treatment of Glatiramer Acetate and Minocycline affects phenotype expression of blood monocyte-derived dendritic cells in Multiple Sclerosis patients. J Neuroimmunol 197 2 (2008) 140-146
60. Festoff B.W., Ameenuddin S., Arnold P.M., Wong A., Santacruz K.S., and Citron B.A. Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal cord injury. J Neurochem 97 (2006) 1314-1326
61. Price C., Makintubee S., Herndon W., and Istre G.R. Epidemiology of traumatic spinal cord injury and acute hospitalization and rehabilitation charges for spinal cord injuries in Oklahoma, 1988-90. Am J Epidemiol 139 (1994) 37-47
62. Bracken M.B. Treatment of acute spinal cord injury with methylprednisole: results of a multicenter, randomized clinical trial. J Neurotrauma 8 (1991) S47-S50
63. Short D.J., Masry W.S., and Jones P.W. High dose methylprednisolone in the management of acute spinal cord injury-a systematic review from a clinical perspective. Spinal Cord 38 (2000) 273-286
64. Springer J.E., Azbill R.D., and Knapp P.E. Activation of the caspase-3 apoptotic cascadein traumatic spinal cord injury. Nat Med 5 (1999) 943-946
65. Le Y.L., Shih K., Bao P., Ghirmikar R.S., and Eng L.F. Cytokine chemikine expression in contused rat spinal cord. Neurochem Int 36 (2000) 417-425
66. Baptiste D.C., and Fehlings M.G. Update on the treatment of spinal cord injury. Prog Brain Res 161 (2007) 217-233
67. Yune T.Y., Lee J.Y., Jung G.Y., Kim S.J., Jiang M.H., Kim Y.C., et al. Minocycline alleviates death of oligodendrocytes by inhibiting pro-nerve growth factor production in microglia after spinal cord injury. J Neurosci 27 (2007) 7751-7761
68. Bosch L.V.D., Tilkin P., Lemmens G., and Robberecht W. Minocycline delays onset and mortality in a transgenic model of ALS. Neuroreport 13 8 (2002) 1067-1970
69. Kriz J., Nguyen M.D., and Julien J.P. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 10 3 (2002) 268-278
70. Traynor B.J., Bruijn L., Conwit R., Beal F., O'Neill G., Fagan S.C., et al. Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology 67 1 (2006) 20-27
71. Gordon P.H., et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 12 (2007) 1045-1053
72. Smith D.L., Woodman B., Mahal A., Sathasivam K., Ghazi-Noori S., Lowden P.A., et al. Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Ann Neurol 54 2 (2003) 186-196
73. Stack E.C., Smith K.M., Ryu H., Cormier K., Chen M., Hagerty S.W., et al. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntungton's disease mice. Biochim Biophys Acta 1762 (2006) 373-380
74. Vonsattel J.P., and DiFiglia. Huntington disease. J Neuropathol Exp Neurol 57 5 (1998) 369-384
75. Ryu J.K., Choi H.B., and Malarnon J.G. Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage and neuronal loss in an excitotoxic animal model of Huntington's disease. Neuroscience 141 (2006) 1836-1848
76. Ferrante R.J., Andreassen O.A., Dedeoglu A., Ferrante K.L., Jenkens B.G., Hersch S.M., et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci 22 (2002) 1592-1599
77. Bonelli R.M., Hodi A.K., Hofmann P., and Kapfhammer H.P. Neuroprotection in Huntington's disease: a 2-year study on minocycline. Int Clin Psychopharmacol 19 (2004) 337-342
78. Bonelli R.M., Heuberger C., and Reisecker F. Minocycline for Huntington's disease: an open label study. Neurology 60 5 (2003) 883-884
79. Thomas N., Ashizawa T., and Jankovic J. Minocycline in Huntington's disease: a pilot study. Mov Disord 19 (2004) 692-695
80. Reynolds N. Revisiting safety of minocycline as neuroprotection in Huntington's disease. Mov Disord 22 2 (2007) 292
81. Casarejos M.J., Menendez J., Solano R.M., Rodriguez-Navarro J.A., Yebenes J.G., and Mena M.A. Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. J Neurochem 97 (2006) 934-946
82. Du Y., Ma Z., Lin S., Dodel R.C., Gao F., Bales K.R., et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci 98 25 (2001) 14669-14674
83. Peng J., Xie L., Stevenson F.F., Melov S., Di Monte D.A., and Anderson J.K. Nigrostriatal dopaminergic neurodegeneration in the Weaver mouse is mediated via neuroinflammation and alleviated by minocycline administration. J Neurosci 26 45 (2006) 11644-11651
84. Racette B., Deppen P., Dewey R.B., Scott B., Field J., Carter J., et al. A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin Neuropharmacol 31 3 (2008) 141-150
85. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81 2 (2001) 741-766
86. Suh Y.H., and Checler F. Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharm Rev 54 3 (2002) 469-525
87. Hunter C.L., Quintero E.M., Gilstrap L., Bhat N.R., and Grandhelm A.C. Minocycline protects basal forebrain cholinergic neurons from mu p75-saporin immunotoxic lesioning. Eur J Neurosci 19 12 (2004) 3305-3316
88. Seabrook T.J., Jiang L., Maier M., and Lemere C. Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice. Glia 53 (2006) 776-782
89. Rogers J., Strohmeyer R., Kovelowski C.J., and Li R. Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide. Glia 40 (2002) 260-269
90. Familian A., Boschuizen R.S., Eikelenboom P., and Veerhuis R. Inhibitory effect of minocycline on amyloid beta fibril formation and human microglial activation. Glia 53 (2006) 233-240
91. Familian A., Eikelenboom P., and Veerhuis R. Minocycline does not affect amyloid beta phagocytosis by human microglial cells. Neurosci Lett 416 1 (2007) 87-91
92. Ryu J.K., Franciosi S., Sattayaprasert P., Kovelowski P., Kim S.U., and McLarnon J.G. Minocycline inhibits neuronal death and glial activationinduced by beta-amyloid peptide in rat hippocampus. Glia 48 (2004) 85-90
93. Ryu J.K., and McLarnon J.G. Minocycline or iNOS inhibition block 3-nitrotyrosine increases and blood-brain barrier leakiness in amyloid beta-peptide-injected rat hippocampus. Exp Neurol 198 2 (2006) 552-557
94. Kandel E.R. The molecular biology of memory storage: a dialogue between genes and synapses. Science 294 5544 (2001) 1030-1038
95. Harding H.P., Novoa I., Zhang Y., Zeng H., Wek R., Schapira M., et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell 6 5 (2000) 1099-1108
96. Chen A., Muzzio I.A., Malleret G., Bartsch D., Verbitsky M., Pavlidis P., et al. Inducible enhancement of memory storage and synaptic plasticity in transgenic mice expressing an inhibitor of ATF4 (CREB-2) and C/EBP proteins. Neuron 39 4 (2003) 655-669
97. Harding H.P., Zhang Y., and Ron D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 397 6716 (1999) 271-274
98. Burgos-Ramos E., Puebla-Jimenez L., and Arilla-Ferreiro E. Minocycline provides protection against β-amyloid (25-35) induced alterations of the somatostatin signaling pathway in the rat temporal cortex. Neuroscience 154 4 (2008) 1458-1466
99. Gough A., Chapman S., Wagstaff K., Emery P., and Elias E. Minocycline-induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. Br Med J 312 (1996) 169-172